Thyroid function was evaluated clinically and biochemically in I2 patients with ischaemic heart disease receiving 200 mg oral amiodarone three times daily for periods up to 6 weeks. During drug administration, no patient developed clinical or laboratory evidence of hypothyroidism, but serum levels of T3 tended to fall and those of T4 increased but not to levels outside the normal range. Amiodarone produced a significant reduction in heart rate with prolongation of the QTc interval of the electrocardiogram without altering either the PR interval or the QRS duration. These effects of the drug were still present 4 weeks after cessation of treatment.
Thyroid function was evaluated clinically and biochemically in I2 patients with ischaemic heart disease receiving 200 mg oral amiodarone three times daily for periods up to 6 weeks. During drug administration, no patient developed clinical or laboratory evidence of hypothyroidism, but serum levels of T3 tended to fall and those of T4 increased but not to levels outside the normal range. Amiodarone produced a significant reduction in heart rate with prolongation of the QTc interval of the electrocardiogram without altering either the PR interval or the QRS duration. These effects of the drug were still present 4 weeks after cessation of treatment.
In spite of the high iodine content, amiodarone does not, therefore, depress thyroidfunction to any important degree during chronic administration and its antianginal action does not appear to be caused by the production ofgeneralized hypothyroidism.
Amiodarone,2 a benzfuran derivative which shares structural similarities with thyroxine ( Fig. I) , has been used recently in the treatment of angina (Vastesaeger, Gillot, and Rasson, I967; Barzin and Freson, I969) and cardiac arrhythmias (Van Schepdael and Solvay, I970). It produces bradycardia, coronary dilatation, and a depression of myocardial oxygen consumption, without a significant effect on cardiac output (Charlier et al., I968) . The drug also antagonizes the effects of sympathetic nerve stimulation, but unlike propranolol it does not produce competitive beta-adrenergic receptor blockade (Charlier, I970) . Amiodarone is devoid of local anaesthetic properties and the antiarrhythmic effects of the compound, well defined in experimental animals (Singh and polarization of the action potential. The overall change was similar to that seen in hypothyroidism (Freedberg, Papp, and Vaughan Williams, I970) , and it was significant that the effects on the action potential could be prevented by the simultaneous administration of thyroxine (Singh and Vaughan Williams, I970) .
Benziodarone, an earlier benzfuran derivative, was withdrawn from clinical use because it produced hypothyroidism (Harrison and Cameron, I965) . Whether or not amiodarone might also induce generalized hypothyroidism of clinical significance has not been convincingly established. The present study was, therefore, undertaken to evaluate the effects of the drug on thyroid function in patients with ischaemic heart disease.
Patients and methods
Twelve patients with ischaemic heart disease were selected from the Cardiology Deparanent and Coronary Care Follow-up Clinic of Green Lane Hospital. The majority of the patients had proven myocardial infarction 6 to 8 weeks before entry into the study. Patients who were on digoxin therapy or beta-adrenergic blocking drugs were excluded. Before amiodarone was given, each patient was interviewed and examined for evidence of thyroid dysfunction; particular attention was paid to heart rate and blood pressure. When all baseline data were obtained, amiodarone was started in a dose of 200 mg 3 times daily and continued for 6 weeks. After 3-and 6-week periods of treatment with the drug, heart rate, blood pressure, QTc interval on the electrocardiogram as well as thyroid function were assessed. The drug was then discontinued and all measurements repeated 4 weeks later.
Results
Of the I2 patients entering the investigation programme, 9 completed the protocol. Of the 3 who did not, 2 were withdrawn after a 3-week period of drug administration; i developed left ventricular failure which settled on digoxin and diuretic therapy. The other experienced an episode of severe ischaemic cardiac pain associated with marked T wave inversion in the praecordial leads of the electrocardiogram; these changes, which were not associated with an increase in serum myocardial enzymes, regressed completely, but the patient was not given a further course of treatment with amiodarone. The third patient failed to attend the clinic at the appropriate time, but data were available after 3 weeks of amiodarone therapy. Of the 12 patients studied, 8 had complained of effort angina before entry into the trial. Five of the 8 either became free of pain or were significantly improved when they were given amiodarone. The remainder had mild symptoms only and derived no benefit from the drug.
Thyroid function
None of the patients had clinical or laboratory evidence of thyroid disease before amiodarone was started. All patients given amiodarone remained clinically euthyroid during the entire period of drug administration. Mean half relaxation time of the ankle jerks before treatment was 246 ± 44 (± SD) ms and at the end of treatment, 237 ± 46 (_ SD) ms.
The mean serum cholesterol level at the beginning of therapy was 6.6 ± o.s mmol/l (255 ± i8 (± SD) mg/Ioo ml) and at the time therapy was completed the level was 7.0 ± o.8 mmol/l (269 ± 33 (± SD) mg/ioo ml). Analysis of paired samples showed no significant difference in either of these indices of possible hypothyroidism.
After 3 weeks of treatment with amiodarone, serum PBI in all patients rose to immeasurably high levels. The increase was attributable to the iodine content of amiodarone and provided confirmatory evidence that the patients were taking the tablets. Good laboratory evidence against the development of primary hypothyroidism (Evered et alteration in the levels of thyroxine-binding proteins. The changes in the serum levels of T3 and T4 during amiodarone therapy are shown in Fig. 2 drug, T3 levels fell significantly (P <O.OI) and remained low (P<o.oi) after 6 weeks of therapy. After cessation of amiodarone intake, the levels of T3 tended to rise again but recovery was not complete 4 weeks later. Changes were not monitored thereafter. It is noteworthy, however, that though serum T3 levels fell significantly during the administration of amiodarone, the actual values of the hormone in the serum usually remained within the normal range for the laboratory. An opposite trend in the serum T4 levels during amiodarone administration was found. Serum T4 increased in all patients who took the drug for a period greater than 3 weeks (Fig. 3) but, as in the case of T3 levels, the absolute levels remained within the laboratory range of normal values. The differing directional change in T4 and T3 levels during amiodarone therapy is reflected in the pronounced alteration in the T4/T3 ratio. Before amiodarone was given, this mean ratio was 8I ±8 (n= I2); 6 weeks after amiodarone treatment it rose to I79 ± 7 (n=8). The change was highly significant (P < o.ooi).
Cardiovascular effects
The changes in heart rate and the QTc interval on the electrocardiogram during amiodarone administration are presented in Fig. 4A and B. Three weeks after amiodarone was started, the mean reduction in heart rate for the group was about I0 per cent; at 6 weeks, it was about IS per cent. When the drug was withdrawn, heart rate tended to increase, but recovery was not complete 4 weeks later. There were no significant changes in systolic or diastolic blood pressures throughout the entire period of study. Fig. 4B . During amiodarone therapy a significant prolongation in the QTc interval was demonstrated in all patients, the maximal effect occurring 3 weeks after the start of the drug. Fig. 5 illustrates the change in 2 patients. It will be seen that in patient A whose control heart rate was low (55/min), prolongation in the QTc interval occurred without a further reduction in rate. In patient B, bradycardia as well as lengthening of the QTc interval were produced by amiodarone. These changes persisted during continued administration of amiodarone, and significant prolongation of the QTc interval was still evident 4 weeks after stopping the drug. There were no changes in the QRS duration or the PR interval during the period of drug therapy.
Discussion
The data presented here confirm previous observations (Facquet et al., I970) that chronic administration of amiodarone in patients with cardiac disease leads to the development of a moderate degree of bradycardia of gradual onset associated with a significant degree of prolongation of the QTc interval of the electrocardiogram. Our results provide further and reasonably decisive evidence that these changes, which were found to regress slowly on withdrawal of treatment, are not caused by impaired thyroid function. However, it was of interest to find that the drug produced a significant increase in the levels of T4 in association with a comparable decline in serum T3 levels. The reason for these contrasting effects is not clear but may be related to the iodine load produced by amiodarone which has 37.2 per cent iodide by weight. Under these circumstances, it may be speculated that a preferential synthesis of T4 in the thyroid gland occurs at the expense of T3. On the other hand, the possibility that an effect on T4 metabolism by an inhibition of peripheral breakdown of T4 to T3 (Larsen, I972) , which may also account for the observed changes in the levels of these hormones during therapy, cannot be excluded.
The efficacy of amiodarone as an antianginal agent is now well established (Vastesaeger et al., I967; Barzin and Freson, I969) . In chronic animal studies (Charlier et al., I968 ) the drug was found to affect the major determinants of myocardial oxygen consumption. The development of significant bradycardia in our own studies in anginal patients would also imply a reduction in myocardial oxygen utilization contributing to the drug's antianginal efficacy. Barzin and Freson (I969) found that amiodarone produced a fall in the values of the rate-systolic pressure product which has been used as an index of myocardial oxygen utilization (Robinson, I967) . Our own small study was not designed to evaluate the antianginal efficacy of amiodarone, but it is nevertheless of interest that an improvement in symptoms was found in the majority of our patients. The occurrence of severe chest pain with ischaemic changes in the electrocardiogram occurring during amiodarone therapy in one patient seems fortuitous. It has not been reported in other studies in which amiodarone was given to large numbers of patients for prolonged periods of time (Vastesaeger et al., I967) . Similarly, the development of left ventricular failure in another patient may not have been related to drug treatment. Amiodarone is unlikely to alter the adrenergic drive to the heart since it produces a weak non-cempetitive sympathetic antagonism, with little effect on left ventricular function (Charlier et al., I968; Charlier, I970) . Barzin and Freson (I969) have shown that cardiac output after I month's treatment with a daily dose of 600 mg amiodarone was not altered significantly, even in those patients who had cardiac decompensation.
The electrocardiographic changes during amiodarone therapy found in our study are of particular significance in relation to the mechanism of the drug's known antiarrhythmic actions in animals (Singh and Vaughan Williams, I970) and Varnauskas (I973) in man. Using suction electrodes, these authors showed that chronic administration of amiodarone in patients led to a prolongation in the repolarization phase of the monophasic right atrial action potential. These results are of special interest in relation to the finding that patients with a tendency to relapse to atrial fibrillation after DC conversion to sinus rhythm had more rapid atrial repolarization than those who maintained sinus rhythm (Olsson, Cotoi, and Varnauskas, I97I) . Accelerated repolarization of the atrial action potential has also been reported in experimental thyrotoxicosis, and the converse in hypothyroidism (Freedberg et al., I970) . The effects of amiodarone on atrial fibrillation in thyrotoxicosis and on the relapse rate after cardioversion of this arrhythmia in other conditions may thus be of interest.
A feature of interest suggested by the results of the present investigations when considered in relation to those of our previous study (Singh and Vaughan Williams, 1970) 
